OpenAI’s new model, called GPT-4b micro, was trained to suggest ways to re-engineer the protein factors to increase their function. According to OpenAI, researchers used the model’s suggestions to change two of the Yamanaka factors to be more than 50 times as effective—at least according to some preliminary measures.

Seems that OpenAI is diversofying its AI models to cover more fields of science… and business. They’re doing this research by investing in Retro Bioscience, a company that focuses on longevity science. The shaddy part is that Sam Altman, CEO of OpenAI, is also a co-founder of Retro Bioscience. Nevertheless, it’s a great example of how AI can be used to solve real-world problems.